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ABSTRACT 
The human gamma-herpesvirus Epstein-Barr virus (EBV) has been implicated in the 
pathogenesis of a broad spectrum of lymphoid and epithelial cell malignancies. A 
characteristic property of the virus is the capacity to establish a non-productive growth-
promoting infection in B-lymphocytes. Although the induction of cell proliferation is a key 
feature in oncogenesis, it is not sufficient for full malignancy. In the work presented in this 
thesis my colleagues and I have asked whether the virus might contribute to oncogenesis by 
triggering additional events that are required for tumor progression. Replicative immortality 
is dependent on the activation of mechanisms that maintain the integrity of telomeres. 
Malignant cells achieve this by activating telomerase or a recombination-dependent pathway 
known as alternative lengthening of telomeres (ALT). We observed multiple signs of 
telomere dysfunction consistent with the activation of ALT in newly EBV infected B-
lymphocytes. These include accumulation of telomere-associated promyelocytic leukemia 
nuclear bodies (APBs), telomeric-sister chromatid exchange (T-SCE), and low expression of 
telomere associated proteins such as TRF1, TRF2, POT1, and ATRX, pointing to telomere 
de-protection as possible cause of telomere damage. The early phase of EBV induced B-cell 
immortalization is characterized by the accumulation of DNA damage and activation of a 
DNA damage response (DDR) that limits the efficiency of growth transformation. By 
comparing the response of B-lymphocytes infected with EBV or stimulated with a potent B-
cell mitogen, we found that significant higher levels of damage occur in EBV infected blasts 
due to stronger and sustained accumulation of reactive oxygen species (ROS). Quenching of 
ROS did not affect the kinetics and magnitude of viral gene expression but dramatically 
decreased the efficiency of B-cell transformation, which correlated with selective 
downregulation of the viral LMP1 and the phosphorylated form of the cellular transcription 
factor STAT3. Analysis of the mechanism by which high levels of ROS support LMP1 
expression revealed selective inhibition of viral microRNAs that target the LMP1 transcript. 
Viral products that are delivered to the infected cells by the incoming virions are likely to 
play important roles in regulating the cellular response to infection. One of such products, the 
large tegument protein BPLF1, is a cysteine protease with potent ubiquitin and NEDD8-
specific deconjugase activities. We found that targeting of the deneddylase activity of BPLF1 
to nucleus of productively infected cells requires processing of the catalytic N-terminus by 
caspase-1. Inhibition of caspase-1 severely impairs viral DNA synthesis and the release of 
infectious viruses. Collectively, the findings summarized in this thesis provide new insights 
on the capacity of EBV to contribute to tumor initiation and progression by triggering events, 
such as oxidative stress and ALT, that favor the acquisition of both genomic instability and 
replicative immortality. Regulation of viral functions by the cellular response to danger 
signals delivered by incoming virions may further contribute to the remodeling of the host 
cell environment allowing successful infection.  
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1 FOREWORD 
 
According to conservative estimates approximately 20% of all human cancers arise as the 
consequence of infections. Some infections are necessary and sufficient for the establishment 
and persistence of the malignant phenotype, while others are probably co-factors of cancer 
development. In addition, infection may also act indirectly by suppressing the host immune 
response and cancers arising under these conditions are frequently linked to the reactivation 
of latent tumor viruses. Understanding the biology of tumor-associated infections has 
significantly improved the outcomes of some cancers, as illustrated by the prevention of liver 
cancers by hepatitis B virus (HBV) vaccination of newborn children in Taiwan 1 and the 
reduction of cervical carcinoma precursor lesions in girls vaccinated against HPV16 and 
HPV18 2. Highly active anti-retrovirus therapy (HAART) has substantially reduced the 
incidence of Kaposi’s sarcomas and Epstein-Barr virus-associated B-cell lymphomas in 
human immunodeficiency virus (HIV)-infected patients 3, and new drugs against persistent 
hepatitis C virus (HCV) infections will probably reduce the incidence of HCV-associated 
liver cancers 4.  
 
Tumor viruses cause the majority of infection-associated cancers. Seven families of human 
tumor viruses are currently known. These include five DNA viruses: Epstein-Barr virus 
(EBV, HHV4) and Kaposi’s sarcoma associated herpesvirus (KSHV, HHV8), the 
hepadnavirus HBV, several members of the alpha- and beta- families of oncogenic human 
papilloma viruses (HPVs) and a newly discovered polyomavirus that causes Merkel cell 
carcinoma (MCV); and two RNA viruses: the flavivirus HCV and the retrovirus that causes 
human T-cell leukemia (HTLV1). A common property of these viruses is their capacity to 
establish persistent infections in the majority of individuals worldwide or within populations 
where virus is endemic and the associated diseases occur at higher incidence. In the majority 
of individuals the infection is either asymptomatic or accompanied by benign proliferations 
that often appear in concomitance with disturbances of the host immune responses and tend 
to regress spontaneously once full immunocompetence is restored. Thus, viral infection acts 
as an “initiating event” while tumor progression is mediated by multiple genetic or epigenetic 
changes that enhance cell proliferation and provide the means to avoid immune control. A 
corollary of this scenario is the expression of viral gene products that drive virus replication 
by regulating the proliferation, apoptosis and immunogenicity of virus infected cells and 
halting immune responses.  
 
Studies of viral oncogenesis have mainly dealt with the capacity of viral oncoproteins to 
interfere with critical cellular functions such as cell division, apoptosis, differentiation and 
interaction with the environment. However, the long delay between primary infection and the 
development of malignancies, together with the monoclonality of the tumors suggest that 
tumor progression requires multiple genetic and epigenetic changes. Critical properties 
acquired during tumor progression include the capacity to escape differentiation programs 
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and senescence, independence from growth regulatory factors, inactivation of apoptotic 
responses, the ability to induce the formation of blood vessels and the capacity to leave the 
original tissue environment and establish distant metastasis. In addition to the activity of viral 
oncoproteins, each of these properties may be acquired through the genetic or epigenetic 
alteration of cellular genes, a phenomenon collectively known as genomic instability 5. 
Telomere dysfunction associated with alterations of the machinery that maintains telomere 
homeostasis plays a major role in the induction of genomic instability. Different types of 
genetic alterations have been identified in virus-associated malignancies and there is evidence 
for a causative role of viral proteins in their occurrence. An important mechanism by which 
viruses may promote genomic instability is their capacity to interfere with the host DNA 
damage response (DDR). DNA tumor viruses manipulate the DDR in multiple ways. This 
often involves the expression of viral proteins that may either activate a growth-suppressive 
DDR in response to proliferation-induced replicative stress, or mitigate the DDR either 
downstream, by modulating apoptosis, or upstream by attenuating the strength of the 
oncogenic signal. A key aspect of viral oncogenesis is the capacity of the virus to reprogram 
the host cell environment in order to counteract the cell intrinsic and innate immune defense. 
The early events following virus entry are likely to play a pivotal role in determining the fate 
of the infection at the cellular level. Thus, virion-associated viral products may serve an 
important function in oncogenesis by allowing the establishment of a stable virus-host cell 
interaction that could progress to malignancy. 
 
In the work described in this thesis, my colleagues and I have focused our attention on the 
early consequences of EBV infection in B-lymphocytes with the aim to understand whether 
and through which mechanisms the virus is capable of initiating the cascade of events that 
leads to malignant transformation. 
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2 INTRODUCTION 
 
2.1 EPSTEIN-BARR VIRUS 
Epstein-Barr virus (EBV, or human herpesvirus-4 HHV4) is a ubiquitous human γ-
herpesvirus that infects the majority of adults globally. It was first detected in 1964 in a cell 
line derived from an African Burkitt’s lymphoma, and it is the first recognized human tumor 
virus 6. Asymptomatic primary infection normally occurs during childhood and is 
accompanied with the establishment of life-long protective immunity 7. However, delayed 
primary infection may cause a self-limiting lymphoproliferative disease known as infectious 
mononucleosis (IM), while in immunosuppressed patients EBV might cause aggressive B-
cell lymphomas 8 9. 
The prototype EBV derived from the B95.8 cell line has a 184 kbp double-stranded DNA 
genome that encodes for more than 85 open reading frames (ORFs) 10. The viral DNA 
contains two to five 0.5 kbp tandem terminal repeats (TRs), and six to twelve 3 kbp internal 
repeats (IRs) that divide the genome into short and long unique domains. Fusion of the TRs 
during the early phase of infection leads to the formation of viral episomes that remain 
anchored to the cellular chromatin and replicate together with the cellular DNA in latently 
infected cells. 
2.1.1 EBV pathogenesis 
EBV is implicated in the pathogenesis of a wide spectrum of lymphoid and epithelial 
malignancies, including Burkitt’s lymphoma, a subset of Hodgkin’s lymphoma, post-
transplant lymphoproliferative disorders (PTLD), a subset of T and NK cell lymphomas, 
nearly all nasopharyngeal carcinomas (NPC) and approximately 10% of gastric carcinomas 
11.  
Burkitt’s lymphoma (BL) is a B-cell malignancy. Almost all the endemic BLs are EBV 
positive while only 10% of the sporadic BLs carry the virus 12. All Burkitt’s lymphomas carry 
chromosomal translocations that place the c-Myc close to the enhancer region of either 
immunoglobulin heavy or light chains, resulting in constitutive activation of this oncogene 13. 
The aberrant activation of c-Myc is the key factor in the pathogenesis of BL 14 15. Agents like 
malaria or HIV act as co-factors in the pathogenesis of BLs, possibly through their capacity 
to provide a chronic stimulus for B-cell proliferation, which may promote the occurrence of 
c-Myc chromosomal translocations. 
Hodgkin’s lymphoma (HL) is an unusual tumor since the malignant Hodgkin Reed Sternberg 
(HRS) cells are only a minor component of the tumor mass. Histologically here are three 
different subtypes of HL: the nodular sclerosis (NS), the mixed cellularity (MC) and the 
lymphocyte-depleted (LD). Of those only the mixed cellularity subtype is consistently 
associated with EBV. The role of EBV in the pathogenesis of the tumor is still unclear but the 
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expression of virus encoded membrane proteins such as LMP1 and LMP2A/2B suggests that 
the activation of signal transduction pathways may be a key event in the pathogenesis 16 17. 
Post-transplant lymphoproliferative disorder (PTLD) is a B-cell lymphoma that occurs when 
T-cell immunity is strongly suppressed, such as in organ and bone marrow transplant 
recipients or AIDS patients 18. Most of the PTLDs are EBV positive and may regress upon 
reestablishment of specific immunity following cessation of immunosuppressive therapy or 
adoptive transfer of EBV specific T lymphocytes. These evidences indicate that PTLDs are 
the effect of a direct outgrowth of EBV transformed B-cells in the absence of T-cell mediated 
immunity 19.  
Nasopharyngeal Carcinoma (NPC) is an epithelial cell tumor that most commonly occurs in 
South East Asia and Northern Africa, which indicates the importance of genetic 
predisposition and environmental cofactors such as dietary habits. Almost all the NPC cases 
are associated with EBV infection 20 and approximately 50% of the tumors express the 
oncoprotein LMP1 at high levels, suggesting a possible role of the viral protein in 
pathogenesis 20 21. 
 EBV is found in approximately 10% of gastric carcinoma (GC) 22 23 24. EBV positive GCs 
are genetically and phenotypically different from the EBV negative GCs 25. As for NPC, the 
exact role of EBV in the pathogenesis of GC is still unclear, although some evidence suggests 
that infection may be a late event in pathogenesis since EBV negative pre-neoplastic gastric 
lesions are also observed 26. 
2.1.2 The EBV life cycles 
Similar to other herpesviruses, EBV infects different cell types where it establishes 
prevalently latent or productive infections. Latent infection usually occurs in B-lymphocytes 
where a limited number of “latency associated” viral gene products promote cell proliferation, 
immune evasion, viral episome maintenance and modification of cellular environment. 
Productive infection is predominant in epithelial cells where it is accompanied by the 
expression of most of the viral genes and production of infectious viral particles 27. In latently 
infected cells, the replication of viral genomes is dependent on the cellular DNA replication 
machinery and occurs only once during the S-phase starting from the viral origin of latent 
replication, OriP 28. In contrast, during productive infection replication of the viral genome 
mediated by the viral DNA polymerase is initiated from the origin of lytic replication, OriLyt, 
and through a rolling circle method, generates more than one genome copies from each 
template.  
EBV infection of B-lymphocytes is initiated by binding of the virus to the CD21 and the 
human leukocyte antigen (HLA) class II receptors. Binding of the viral glycoprotein 
gp350/220 to CD21 brings the virus close to the B-cell surface, whereas a stable complex of 
gp42 with gHgL and gB binds to HLA class II and mediates membrane fusion and virion 
entry 29. Binding of gp350/220 to CD35 may promote infection of CD21 negative but HLA 
class II positive B cells 30. In vitro, EBV infects CD21 negative and HLA class II negative 
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epithelial cells with much lower efficiency. Direct contact of apical cell membranes with 
EBV-infected lymphocytes, entry of cell-free virions through basolateral membranes 
mediated by interaction of the BMRF2 glycoprotein with β1 integrin, and cell-to-cell 
transmission of virus across lateral membranes were proposed as potential mechanisms 31.  
After entering into the cytoplasm of B-lymphocytes, the virions are disassembled at the 
nuclear pore and the viral DNA is translocated to the nucleus where viral gene expression is 
initiated. Growth-transformation of the infected cells is induced by the expression of nine 
latent proteins. EBV infected blasts that migrate to lymph nodes are rescued from germinal 
center selection by the expression of viral proteins that inhibit apoptosis. The surviving cells 
may differentiate into memory B-cells with restricted viral gene expression, or occasionally 
into plasma cells that are permissive for virus replication. EBV carrying memory B cells with 
either no or very restricted expressions of viral genes are found in the circulation of all 
healthy EBV carriers. When these cells circulate within the lymphoepithelial tissues of the 
tonsils and nasopharynx, reactivation of the productive cycle may occur, resulting in 
productive infection of epithelial cells and release of large amount of virus in the saliva. Thus, 
a persistent infection state is established, which is characterized by latent infection of B cells 
as well as infrequent virus reactivation in B cells and epithelial cells 32 (Figure 1). 
 
Figure 1. EBV life cycle (modified from Murray and Young, 2001). EBV infection of B cells is mostly latent and induces 
growth-transformation, whereas infection of epithelial cells is productive and induces virus replication. After primary 
infection of B cells, the outgrowth of transformed cells is controlled by EBV specific cytotoxic T cells that are re-activated 
from virus specific memory T-cell pool. The infected cells that survive successfully become EBV carrying memory B cells. 
Some latently infected B cells could become permissive for virus reactivation from time to time. Infectious virions released 
from these cells could initiate a new round of infection of both epithelial cells and B cells. Thus a persistent EBV infection is 
established, which is featured by latent infection in circulating B cells and occasional virus reactivation in B cells and 
epithelial cells. 
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2.1.2.1 Latent infection and latency products 
Following entry of the virus into B-lymphocytes and circularization by fusion of the TRs, the 
EBV episomes are anchored to the host cell DNA. Due to extensive methylation of the viral 
genome only a small number of latency genes is expressed 33. Four latency programs (latency 
0, I, II and III) characterized by a distinct pattern of viral gene expression have been 
extensively characterized in EBV infected cells 11.  In addition, a pre-latency concept has 
been proposed recently to describe the period immediately following EBV infection and 
before cell division.  
Within two hours of infection, multiple EBV transcripts are detected by sensitive PCR. These 
include the mRNAs for the latency genes EBNA2, EBNA-LP and non-coding RNAs EBER1 
and EBER2, as well as the lytic immediate early genes BZLF1 and BRLF1, the viral immune 
evasins BCRF1, BGLF5 and BNLF2a; and the virus encoded apoptosis antagonists BHRF1 
and BALF1 34. This transient expression of lytic genes during the pre-latent phase is the 
consequence of virion associated RNAs entry during infection, and they do play important 
roles for establishing early infection 35. Due to the incapability to initiate transcription, the 
mRNA levels of lytic genes rapidly decline, while the transcripts starting from the Wp 
promoter that prevalently encode for EBNA2 and EBNA-LP accumulate and activate the 
stronger latency promoter Cp 36. This will lead to the establishment of latency III where 
EBNA3 proteins, EBNA1 and the LMPs are expressed 36 37. Post-transplant 
lymphoproliferative disorder (PTLD) and establishment of immortalized lymphoblastoid cell 
lines (LCLs) represent the latency III type of EBV infection in vivo and in vitro respectively.    
While EBV infected B cells are maintained at latency III (growth transformation) in vitro, a 
more complicated scenario describes the establishment of latent infection in vivo. Since the 
EBV specific cytotoxic T-lymphocytes could recognize many epitopes derived from the 
latency proteins, the latency III infected B cells are either eliminated or pressured to migrate 
into germinal centers where the latency II program is expressed. Latency II is characterized 
by expression of EBNA1 from the Qp promoter, together with the three latent membrane 
proteins LMP1, -2A and -2B from the bidirectional LMP promoter. This type of latency can 
be detected also in a subset of Hodgkin’s lymphomas (HD), and it is considered that cells 
expressing latency II phenotype are the potential precursors for the HRS cells 38. It is yet not 
clear what kind of factors drive the transition from latency III to latency II but it was shown 
that T cell secreted cytokines may diminish the Cp promoter activity, which may down-
regulate the expression of the highly immunogenic EBNAs 39. 
The EBV infected B cells exit the germinal center as resting memory B cells. These cells do 
not express the latency genes (latency 0) or express EBNA1 from the Qp promoter (latency 
I). EBV positive Burkitt’s lymphoma (BL) is the typical representative of latency I associated 
disease 40. In addition, EBV expresses two non-coding RNAs, EBER1 and 2, and several 
microRNAs in all type of latency programs 41. 
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EBNA1 is the only viral protein that is ubiquitously expressed in all EBV-positive 
malignancies 42. EBNA1 encoded by the prototype B95.8 derived EBV is a 641 amino acids 
long protein, which consists of an N-terminal domain that contains two Gly-Arg rich regions 
(GR) spaced by a long Gly-Ala repeat (GAr), and a C-terminal domain that contains a viral 
DNA binding and dimerization domain (DBD) and a nuclear localization signal (NLS). 
EBNA1 forms stable homodimers and binds to the OriP through its DBD domain 43, while 
the GR domains tether the viral episomes to cellular DNA 44 and recruit the cellular origin 
recognition complex (ORC) and the replication protein A (RPA) to initiate replication 45 46 47. 
The GAr stabilizes EBNA1 by inhibiting ubiquitin proteasome-dependent degradation, and 
thereby prevents the presentation of EBNA1 antigens on MHC class I molecules 48 49. Thus, 
EBNA1 plays an essential role in replication, partitioning and maintenance of the viral 
episomes during cell cycle in all types of latency. EBNA1 also acts as both an activator and a 
repressor in viral gene transcription. It binds to OriP and enhances the transcription of other 
latent genes from the Cp and LMP1 promoters 50 51 52 and negatively regulates its own 
expression via interaction with the Qp promoter 53. In addition, EBNA1 has been shown to 
alter the cellular environment by regulating the expression of host cell genes that are involved 
in proliferation, survival and tumor progression. For instance, it was reported that EBNA1 
binds to sequence motifs close to the transcription initiation sites of various cellular genes 
such as HDAC3, CDC7 and MAP3K1, that are important for sustaining cell proliferation 
signals 54. Expression of EBNA1 was also shown to induce oxidative stress, genomic 
instability and telomere dysfunction in B-cell lymphoma cell lines through activation of the 
NADPH oxidase NOX2 55 56. Moreover, EBNA1 competes with p53 for binding to a pocket 
in the cellular ubiquitin specific protease USP7, which results in destabilization of p53 and 
inhibition of apoptosis in EBV infected cells 57. More recently, EBNA1 was shown to affect 
the chromatin organization by promoting de-compaction similarly to the high mobility group-
A (HMGA) remodelers. Most notably, this effect on the chromatin structure does not require 
the recruitment of ATP-dependent chromatin remodelers, histone acetylases and acetylated 
histone binding proteins. This function of EBNA1 is mediated by the two Gly-Arg rich 
domains (GR), which resemble the AT-hook of HMGAs 58. However, the relationship 
between this chromatin remodeling effect and the transcriptional activity of EBNA1 still 
needs to be better studied. 
EBNA2 is the first viral protein expressed after infection of B-lymphocytes. It is essential for 
EBV induced transformation through its activity as a transcription activator of both viral and 
cellular genes including CD23, c-Myc, CD21 and the EBV latent membrane proteins 59 60. 
EBNA2 does not directly bind the DNA but exerts its transcriptional activity by binding to 
sequence specific DNA binding proteins, such as the recombinant binding protein (RBP)-Jk 
and PU.1 61 62. By activating RBP-Jk mediated transcription, EBNA2 mimics a constitutively 
activated Notch receptor signaling that maintains the cell proliferation signals 63.   
EBNA-LP (EBNA-leader protein or EBNA5) is also expressed early after infection of B-
lymphocytes. EBNA-LP serves as co-activator of EBNA2 on specific promoters, and is 
required for efficient establishment of LCLs though its role is not fully understood 64. The 
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protein interacts with BCL-2 or the EBV homologue BHRF1, to regulate cell death by 
apoptosis 65. Interaction with both the tumor suppressor pRb and p53/MDM2 may enable cell 
cycle progression of infected B cells 66 67. 
The EBNA3 proteins, including EBNA3A, 3B and 3C (also called EBNA3, -4 and -6) are 
transcription regulators encoded from three adjacent ORFs. EBNA3A and EBNA3C are 
essential for EBV induced B-cell transformation, while EBNA3B is dispensable 68. EBNA3 
proteins compete with EBNA2 for binding to RBP-Jk and may thereby repress EBNA2 
mediated gene transactivation 69. EBNA3C can up-regulate CD21 and up- or downregulate 
LMP1 70 71, and inhibit the Cp promoter by recruiting histone deacetylase-1 (HDAC1) 72. 
Moreover, EBNA3C interacts with pRb and cyclin D1 to promote cell cycle progression and 
bypass of the G1 checkpoint 73 74. 
The latent membrane proteins (LMPs) are proteins with several transmembrane domains that 
mimic cellular receptors. LMP1 is required for B-cell transformation and it is the only 
acknowledged EBV oncoprotein 41 75. LMP1 is a functional homolog of human CD40, and 
acts as a constitutively active tumor necrosis factor (TNF) receptor 76 77 78. The carboxy-
terminal of LMP1 consists two C-terminal activating regions (CTAR1 and 2), which mediate 
signaling by direct interaction with the TNF receptor associated factors (TRAFs) or the TNF 
receptor associated death domain (TRADD) 77. Through the CTAR domains LMP1 activates 
a variety of signaling pathways including NF-kB, MAPK kinase, PI3K kinase, extra-cellular 
signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK) and Janus kinase/signal 
transducer and activator of transcription (JAK/STAT) to provide cell proliferation and anti-
apoptosis signals (BCL-2, A20), as well as regulates cytokine production (IL-10) and cell 
surface marker expression (CD21, CD23, CD40, HLA-II etc.) 79 80 81 82 83 84 85 86 87. LMP2A 
and 2B share the 12 transmembrane domains and C-termini, while LMP2A has an extra 119 
amino acid cytoplasmic N-terminal domain that is involved in mimicking the B-cell receptor 
(BCR) function 88 89 90. LMP2A governs virus reactivation through its capacity to promote 
the ubiquitin-dependent proteasomal degradation of the tyrosine kinase Syk and Lyn, and is 
also involved in the transcriptional down regulation of hTERT 90 91 92 93. The function of 
LMP2B is less studied, though it seems to modulate LMP2A activity 94. 
EBER1 and EBER2 are small non-coding RNAs transcribed by the cellular RNA polymerase 
III. They are expressed abundantly in all types of latency. They induce expression of various 
interleukins (IL) in EBV infected malignant and non-malignant cells, including IL-10 in 
Burkitt’s lymphoma cells, insulin-like growth factor (IGF)-1 in nasopharyngeal carcinoma 
and gastric carcinoma cells, IL-9 in T-cell lymphoma cells and IL-6 in transformed B cells 95 
96 97 98 99. Moreover, EBERs can modulate the interferon-dependent antiviral immune 
response by inhibiting the RNA-activated protein kinase (PKR), leading to resistance of PKR 
induced apoptosis 100.  
EBV also encodes microRNAs that regulate gene expression by controlling the stability of 
target mRNAs. There are two clusters of EBV miRNAs in the EBV genome. The BHRF1 
transcript encodes 3 precursors with 4 mature miRNAs, while the BART region encodes 22 
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precursors with 40 mature miRNAs 101 102 103. The EBV miRNAs have distinct expression 
patterns depending on cell type and latency program. For example, BHRF1 miRNAs are 
mostly expressed in latency III and productively infected cells but are hardly detected in 
latency I BL cells and latency II NPC cells 102 104 105 106 107. In contrast, BART miRNAs are 
expressed in all types of infection but especially abundant in epithelial cells 108. These 
discrepancies are due to transcription of BHRF1 and BART miRNAs utilizing different viral 
promoters 108. Infection with miRNA mutants or ectopic expression of single miRNA has 
contributed to elucidate some of the functions of these molecules. The BHRF1 miRNAs were 
shown to promote B cell proliferation, modulate the cell cycle and inhibit apoptosis during 
the early phases of EBV infection 109. A subset of BART miRNAs can suppress the 
expression of LMP1 and regulate the NF-kB pathway in NPC cells 110. Moreover, BART 
miRNAs are also shown to prevent apoptosis by repressing the translation of caspase-3, 
contributing thereby to the proliferation of newly infected B cells 111. 
2.1.2.2 Productive infection  
The physiological signals that trigger the reactivation of latent infection to produce new 
infectious viruses are poorly understood. Spontaneous reactivation is rare in EBV carrying B 
cell lines but can be triggered by cross-linking of surface immunoglobulin (Ig), or treatment 
with tumor promoters such as TPA and sodium butyrate 112 113 114. B-cell receptor cross-
linking is believed to be the stimulus that triggers reactivation of the productive cycle in vivo 
91 115. Following reactivation, the first detected lytic proteins are the immediate early protein 
BZLF1 and BRLF1, which activate the viral promoters that drive expression of early and late 
products 27. Many of the early genes are factors required for viral DNA replication, such as 
the viral DNA polymerase BALF1, the DNA polymerase processivity factor BMRF1, the 
single-stranded DNA binding protein BALF2, the helicase BBLF4, the primase BSLF1 and 
the primase associated protein BBLF2/3. Efficient viral genome replication requires an S-
phase-like cellular environment. This is achieved via manipulation of the DNA damage 
response and cell cycle checkpoints by viral products such as BZLF1 and the large tegument 
protein BPLF1 116 117 118.  After viral replication, the late gene products are expressed. These 
encode mostly structural viral proteins including the nucleocapsid proteins for virion particle 
packaging. Some late gene products contribute to efficient virus production by inhibiting 
apoptosis and counteracting the host immune defenses. For example, BPLF1 suppresses NF-
kB signaling and its downstream pro-inflammatory cytokine in virion producing B cells 119 
120. This tegument protein is incorporated into the viral particles and may also interferes with 
the immune response during a new round of infection by diminishing TLR signaling via its 
ubiquitin deconjugase activity 119. 
 
2.2 DNA DAMAGE, DNA DAMAGE RESPONSE AND DNA DAMAGE REPAIR 
DNA damage is a common event in the life of cells. According to some estimates DNA 
lesions are produced at a rate of 1,000 to 1,000,000 events per cell per day throughout the 
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whole genome 121. There are endogenous sources of DNA damage such as collapsed 
replication forks or oxidative damage induced by reactive oxygen species produced during 
metabolism, and exogenous sources such as exposure to UV light, mutagenic chemicals, 
bacteria toxins and virus infection. The damage can be categorized into three main classes: 
DNA base damages including reduced, oxidized or fragmented bases; backbone damages 
including single and double strand DNA breaks; and DNA inter-strand cross-links or DNA-
protein cross-links. 
2.2.1 DNA damage response  
Cells have evolved several mechanisms to face the threat of damaged DNA and these 
responses are collectively known as DNA damage response (DDR). The DDR enables the 
cells to either repair the damage, or undergo cell cycle arrest and cell death 122. If the rate of 
repair is capable to mend the damaged DNA, the cells can still proliferate. However, if the 
amount of DNA damage exceeds the capacity of the cellular repair machineries, senescence 
and apoptosis that serve as tumorigenesis barrier will be elicited to destroy the cells. In some 
occasions, damaged cells might escape from this self-destructing fate and survive. This 
process may promote further cell proliferation, accumulation of genomic instability, and lead 
to tumor initiation and/or progression 123. 
The cellular DDR is activated in multiple steps. Various sensor proteins first recognize the 
DNA lesions, then the primary protein kinases are activated. These kinases phosphorylate 
target mediator proteins, which are important for initiation of repair process and transmission 
of the DNA damage signals to downstream transducers. The transducers will further amplify 
these signals and phosphorylate effector proteins that determine the cellular response to the 
damage 124 125. Depending on when the damage occurs, several DNA damage checkpoints 
might be activated to halt the cell cycle progression. Besides, various DNA damage repair 
machineries may be elicited to repair different type of DNA lesions. These cellular reactions 
may function independently, though the same DDR signaling components might participate 
in activation of both checkpoints and repair pathways. 
2.2.2 Cell cycle and checkpoints  
The cell cycle can be divided into four phases. The replication of the DNA takes place during 
the synthesis (S) phase, and the equal segregation of doubled DNA copies occurs during 
mitosis (M) phase. The S and M phases are separated by two gap (G) phases named G1 and 
G2. The G1 phase comprises the period between the ending of mitosis to the beginning of 
next round DNA synthesis. During G1, the cell grows and increases its organelles like 
mitochondria and ribosomes, which are important for the coming S phase replications. The 
gap from the end of S phase until the beginning of mitosis is defined as G2, where cells keep 
growing and prepare to divide 126. In mammalian cells, proper progression of the cell cycle is 
regulated by several cyclins and cyclin-dependent kinases (CDKs), while multiple checkpoint 
responses halt this process upon induction of DNA damage to allow repair 127 126. 
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To date, several cell cycle checkpoints have been defined. The G1/S checkpoint prevents 
cells with DNA damage from entering S phase by inhibiting the initiation of replication. The 
intra S checkpoint is activated by the damage induced during S phase or in those cells that 
escaped from the G1/S checkpoint. The G2/M checkpoint prevents the cells from entering 
mitosis while carrying DNA damage in order to avoid aberrant chromosome segregation.  
2.2.3 DNA damage repair  
Different types of DNA damage are repaired by specific repair mechanisms including direct 
repair, base excision repair, nucleotide excision repair, single and double strand break repair, 
and cross-link repair 128. Here, I will briefly summarize several major DNA repair pathways 
with particular focus on DNA double strand break (DSB) repair, which is most relevant for 
this thesis since DSBs are most frequently induced during tumor virus infection. 
The base excision repair (BER) is responsible for repairing oxidized bases, alkylated bases 
and base mismatches. It is initiated by DNA glycosylases that recognize and release the 
damaged base from DNA to form an abasic (AP) site. The sugar residue is then removed by 
an AP endonuclease (APE1 in mammalian) to form a gap that is filled by DNA polymerases. 
The single nucleotide replacement is called short-patch base excision repair while long-patch 
base excision repair replaces 2-10 nucleotides at the damage site 129 130. 
The nucleotide excision repair (NER) is a multistep repair process that removes bulky DNA 
lesions 131. NER utilizes over 30 proteins that exert their function in multiple steps including 
damage recognition, strand dual incisions to bracket the damage lesion, release of the excised 
oligomer sequence, repair synthesis to refill the gap and final ligation of the strand 132 133.  
Single strand DNA breaks (SSB) are normally generated by collapsed replication forks and 
often progress to form DSB. The replication protein A (RPA) coats the damage exposed 
single-strand DNA to prevent degradation or secondary structures formation, and recruits the 
Ataxia Telangectasia and Rad3 related (ATR) kinase and the ATR interacting protein 
(ATRIP) complex 122 134 135 136. The Rad9-Rad1-Hus1 (9-1-1) complex and TopBP1 are also 
loaded to the DNA, possibly for proper activation of the complex 128 137. ATR phosphorylates 
histone H2AX and BRCA1, for repair initiation, and the checkpoint kinase Chk1 that will 
further phosphorylate Cdc25 and p53 to activate the cell cycle checkpoints 138 139 140 141. 
Double strand breaks (DSB) can be generated by various sources such as reactive oxygen 
species, ionizing radiation and genotoxic chemicals, as well as by collapsed replication forks. 
DSBs can be repaired via two distinct mechanisms: an error free mechanism called 
homologous recombination (HR), and an error prone one called non-homologous end joining 
(NHEJ) 142 (Figure 2). 
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Figure 2. DSB repair mechanisms. Two distinct mechanisms of DNA double strand break repair, the homologous 
recombination and the non-homologous end joining, are schematically represented.  
 
2.2.3.1 Homologous recombination  
Homologous recombination (HR) guarantees high fidelity DSBs repair by using a 
homologous template sequence to regenerate lost information at the damaged site. It is active 
mostly during the S/G2 phases where the newly synthesized sister chromatid serves as 
template for repair 143.  
Homologous recombination starts from recognition of the damaged site by the 
Mre11/Rad50/Nbs1 (MRN) complex that senses the damaged DNA and processes the termini 
to generate 3’ single strand DNA overhangs. Rad50 is an ATPase that binds to the DNA, 
whereas the exo-endonucleases Mre11 and Nbs1 process the DNA strands 144. The generated 
3’ overhang is then coated by RPA, while Nbs1 recruits the primary kinase ataxia 
telangiectasia mutated (ATM) kinase 136 145 146. ATM mediates the phosphorylation of histone 
H2AX. Upon phosphorylation by ATM, the Carboxy-terminal interacting protein (CtIP) 
recruits BRCA1 to the damage site and starts an extensive resection of the DNA 147 148. The 
recombinase Rad51 replaces RPA and initiates the repair by promoting strand invasion with 
the help of accessory proteins like BRCA2, forming a displacement loop structure 149 150. This 
is followed by DNA synthesis that extends both the invading and the remaining 3’ ends using 
an intact strand as template, while Rad52 mediates the capture and ligation of both ends that 
results in the formation of a Holliday Junction (HJ) 151. The resolution of HJ by Rad51 and 
XRCC3 generates either crossover or non-crossover products 149. 
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2.2.3.2 Non-homologous end joining  
Non-homologous end joining (NHEJ) repairs DSBs by direct ligation of the two DNA ends. 
It is prevalent in G1 phase since NHEJ does not require a DNA template 152. DNA end 
processing is essential for NHEJ and this could lead to loss of genetic information. The 
process is initiated by recruitment of the Ku70/80 heterodimers at the DNA ends. This 
protects the DNA from further damage and recruits processing factors such as the DNA-
dependent protein kinase (DNA-PK) and the nuclease Artemis that trims the DNA ends 153 
154. Finally, the DNA ends are ligated by the cooperative action of the DNA ligase IV, 
XRCC4-like factor (XLF) and X-rays cross-complementing 4 (XRCC4) 155. 
2.2.4 Tumor viruses manipulate the DNA damage response  
In the recent years it has become clear that successful virus infection is dependent on viral-
mediated manipulation of the host DDR. This involves both a growth-suppressive DDR in 
response to proliferation-induced replicative stress and aberrant activation of the DDR to 
promote virus replication 156. Most tumor viruses infect quiescent cells and drive them into 
the cell cycle to establish an environment conducive for cell immortalization and viral 
genome replication. This aberrant induction of cell proliferation may lead to replicative stress 
and activation of the DDR, which is commonly associated with decreased proliferation. Thus, 
in order to avoid this detrimental fate, many viruses have developed their own machineries to 
regulate the DDR.  
Small DNA viruses usually target the tumor suppressor protein Rb to promote E2F activation 
and cell proliferation. On one hand, this induces replicative stress and activates the DDR 
response, which promotes S phase arrest that is required for virus replication. On the other 
hand, these viruses manipulate DDR downstream effectors, such as p53 to ensure the survival 
of the infected host cells. For example, the coordinated activity of HPV E6 and E7 drives the 
hyper-proliferation of undifferentiated keratinocytes. This is due to the E7-mediated 
inhibition of Rb, which induces replicative stress and activates an ATM/ATR-dependent 
DDR 157 158 159 160 161. Checkpoint-mediated cell cycle arrest is prevented by the E6 protein 
that forms a complex with the cellular E6-AP (E6 associated protein) ubiquitin E3 ligase and 
promotes p53 degradation, thereby antagonizing the DDR-mediated senescence and 
apoptosis 162. Similarly, the SV40 large T antigen induces evasion of the G1 checkpoint by 
interacting with Rb, which activates the ATM pathway 163 164 165. The Large T antigen may 
regulate ATM activity by acting as an upstream activator via binding to the MRN complex 
component Nbs1, and by serving as a phosphorylation substrate 166 167. Accordingly, ATM 
mediated phosphorylation of large T antigen is necessary for replication of the viral genome 
168 169. The virus also encodes viral products that hamper its cell growth suppressive effects. 
Middle T antigen activates phosphatidylinositol 3-kinase (PI3K) and AKT to prevent 
apoptosis in the infected cells 170.  
The large DNA tumor viruses also promote cell proliferation and replicate their episomes 
during S phase. Their large genomes allow for the expression of multiple proteins that 
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interfere with both the activation and repression of the DDR. Inhibition of replicative stress 
signals is required to maintain a successful latent infection. For example, the expression of 
EBNA2 in newly EBV infected B-lymphocytes drives c-Myc induced hyperproliferation 
followed by activation of ATM signaling. Inhibition of both ATM and Chk2 remarkably 
elevates the transformation efficiency, suggesting an inhibitory role of the DDR during the 
early stage of EBV-induced B cell transformation 37. This growth inhibitory effect is 
attenuated by other latency proteins including EBNA3C that acts as an EBNA2 
transcriptional repressor, and LMP1 that inhibits the activity of ATM 171.  
 
2.3 TELOMERES AND TELOMERE HOMEOSTASIS  
The packaging of the eukaryotic cell genome into linear chromosomes poses two problems 
with fundamental biological importance. First, the chromosomes ends must be distinguished 
from double strand breaks (DSBs) to avoid improper DNA damage repair, which could result 
in chromosome end fusions and chromosome breakage during mitosis. Second, the linear 
chromosomes ends cannot be completely replicated by the DNA replication machinery, thus 
DNA sequences are lost during every cell division 172 173. These problems are overcome by 
specialized nucleic acid-protein complexes structures at the chromosome ends known as 
telomeres174. Telomeric DNA consists of G-rich DNA repeat sequences (e.g. TTAGGG in 
human) that buffer DNA erosion and assure the integrity of the coding regions. The length 
varies greatly between species, from approximately 300 bases in yeast to many kilo-bases in 
human 175. The actual terminus of a telomere is not blunt-ended but consists a single-stranded 
3’ tail, known as the G overhang, which is evolutionarily conserved and essential for 
telomeres. Studies have shown large loop structures called telomere loops (T-loops), where 
the single-stranded telomere overhangs curl around in long circles and are stabilized by 
telomere-binding proteins 176. The T-loop structure protects the telomere regions from being 
recognized as DNA double strand breaks. At the very end of the T-loop, the single-stranded 
telomeric DNA invades into a region of double-stranded DNA. The resulting triple-stranded 
structure is called a displacement loop or D-loop 177. Six interdependent telomere-binding 
proteins form the shelterin complex, which consist of the telomeric-repeat-binding factor 1 
and 2 (TRF1 and TRF2), the TRF1-interacting protein 2 (TIN2), the transcriptional 
repressor/activator protein 1 (RAP1), the protection of telomeres 1 (POT1), and the POT1 
and the TIN2 organizing protein TPP1 178. Removal of individual members causes instability 
of the whole structure, which leads to uncapping and de-protection of the telomeres. The 
telomere complex also comprises a non-coding telomeric repeat-containing RNA referred as 
TERRA 179, which is transcribed from subtelomeric regions and interacts with several 
telomere associated proteins such as TRF1, TRF2, the heterochromatin protein 1 (HP1) and 
histone H3 trimethyl K9 (H3K9me3) 180. TERRA plays a key role in maintaining the 
telomere structure and heterochromatin formation along with the shelterin proteins 180. 
Numerous roles of the shelterin proteins in maintaining telomere integrity have been reported. 
For example, TRF2 has been shown to protect human telomeres against DDR activation, 
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since loss of TRF2 activates the ATM kinase and leads to p53 dependent apoptosis 181. TRF2 
and RAP1 hold the T-loop configuration that blocks the Ku70/80 loading, thus preventing 
NHEJ at telomeres and consequent formation of dicentric chromosomes 182 183 184. POT1 
inhibits ATR activation, probably via inhibition of RPA binding at the single stranded 
telomeric DNA 185. TRF1 and TRF2 serve as negative regulators of telomere length, since 
overexpression of these two proteins leads to progressive telomere shortening 186 187. TPP1 
and TIN2 are crucial for POT1 dependent telomere protection by tethering it to TRF1 and 
TRF2 188 189 190 191 (Figure 3). 
 
Figure 3. Telomere structure (modified from Chen et al, 2014). Human telomeres consist multiple TTAGGG sequence 
repeats with single-stranded G-rich 3’ overhangs that curl into double-stranded telomeric DNA regions and form the T loop 
structures. Binding of shelterin proteins stabilizes these loop structures, which protect telomeres from being recognized as 
DSBs. 
 
2.3.1 Telomere maintenance mechanisms  
Telomere shortening due to imperfect linear DNA replication allows limited replication 
cycles of somatic cells due to p53 and p16/Rb dependent senescence when the telomeres are 
consumed 192. Shortening of telomeres and induction of senescence serve as a powerful tumor 
suppressor mechanism. Cancer cells evade this programmed destruction by maintaining the 
length of telomeres via telomerase-dependent and independent mechanisms 193.  
2.3.1.1 Telomerase 
Most cancer cells maintain their telomeres by activating the enzyme telomerase, which is a 
reverse transcriptase complex that adds telomeric repeats onto the chromosome ends using an 
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RNA template 194 195 . Three major components were purified and identified from human 
telomerase, a reverse transcriptase (TERT), a folded RNA containing a telomere repeat 
recognizing sequence and a template (TER), and the small nucleolar ribonucleoproteins 
(snoRNPs) family member dyskerin (DKC1) 196. This enzyme is normally active only in stem 
cells, germ line cells, embryonic tissues and a subset of somatic cells such as activated 
lymphocytes 197, while it is either not expressed or kept at very low levels in most of the 
somatic cells 198. 
The template region of human TER (hTER) is complementary to the telomeric repeat. The 
telomerase promotes binding of the first few nucleotides of the template to the last telomere 
sequence on the chromosome ends, adds a new telomere repeat sequence, sets free the 
telomerase complex, complements the new synthesized 3' ends of telomeres by DNA 
polymerase, and repeats the process. Thus, the conventional replication machinery and 
telomerase are closely coordinated during new telomere synthesis 199. 
The mechanism for telomerase recruitment to telomeres is not completely clear, but at least 
two shelterin proteins, POT1 and TPP1, may provide a physical link between telomerase and 
the shelterin complex 200. TRF1 is proposed to have a negative effect on telomerase 
dependent telomere homeostasis by binding to telomeres and providing a negative feedback 
signal to telomerase 186. 
2.3.1.2 Alternative lengthening of telomeres  
A telomerase-independent mechanism for telomere maintenance, known as alternative 
lengthening of telomeres (ALT), is based on homologous recombination of telomere 
sequences. Evidences for ALT activation in human were first provided by the observation 
that telomere length was maintained after many divisions in cell lines lacking telomerase 
activity 201. The first indication of ongoing recombination was the observation of sharp 
changes in telomere length in telomerase-negative cells 202. ALT cells are characterized by 
the presence of telomere dysfunction induced foci (TIFs), extra-chromosomal telomeres, and 
highly heterogeneous telomere lengths 201 203. Additionally, ALT associated promyelocytic 
(PML) bodies (APBs) that contain PML and telomere DNA are frequently observed 204. 
Although it is generally accepted that telomere elongation in ALT cells requires a DNA 
recombination step, the exact mechanism leading to heterogeneous telomere length is 
uncertain. Two possible not mutually exclusive models have been proposed. 
The first model is based on the finding that telomere sister chromatid exchange (T-SCE) 
occurs much more frequently in ALT cells than in telomerase-positive cell lines or normal 
somatic cells 205 206. The molecular mechanism of T-SCE activation is still unknown, 
although there is evidence that in ALT cells telomeric DNA contains nicks and gaps that may 
serve as a structural barrier to DNA replication and therefore cause T-SCE 207. In this model 
sister chromatid exchanges of unequal size occur during replication, resulting in one daughter 
cell with a lengthened telomere and the other carrying a shortened telomere 208. According to 
the second model, ALT may be achieved using telomeric sequences from close-by 
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chromosomes as templates 209 210, which may result in a net increase of telomeric DNA length. 
In this model, the telomere may also copy its own sequence through T-loop formation, or use 
the telomere sequence of its sister chromatid as template 211. In addition, it has been proposed 
that linear and circular extrachromosomal telomeric DNA could also act as a template for HR 
mediated ALT 210 212 213. 
Several proteins have been shown to be necessary for telomere maintenance in ALT cells. 
The MRN complex (Mre11, Rad50 and Nbs1) promotes ALT activity by recruiting ATM to 
telomeres, which initiates recombination, and by processing the chromosome end to form an 
extended telomeric overhang, which could serve as HR template after invasion of adjacent 
telomere sequences 214 215 216 217 218. The SMC5-SMC6 complex seems to be important for the 
recruitment of telomeres to PML bodies through sumoylation of shelterin proteins, and APB 
is believed to be the platform for ongoing telomeric DNA repair 219 220. RecQ-like helicase 
WRN or BLM are responsible for removing replicating intermediates like G-quadruplexes at 
telomeres, thus loss of them may result in telomere shortening 221. Besides, FEN1, MUS81, 
FANCD2 and FANCA play essential roles in the recombination repair of stalled or broken 
replication forks, which is important for telomere sister chromatid exchange 222 223 224. 
Nevertheless, mutations are often observed in genes that suppress HR in ALT cells, such as 
telomeric heterochromatin remodeler complex ATRX/DAXX and Histone variant 3.3 225 226 
227. 
2.3.2 Tumor viruses and replicative immortality  
Tumor viruses often reprogram the host cells environment to promote proliferation, which 
creates a favorable environment for viral genome replication and enlarges the pool of infected 
cells. A common consequence of tumor virus infection at last is malignant transformation, 
which enables the cells to proliferate indefinitely. However, the telomere erosion during 
replication will finally induce cell senescence, and this machinery serves as an important 
tumorigenesis barrier. Thus, tumor viruses infected cells must evolve a mechanism to bypass 
this blockade. One strategy to achieve it would be to (re)-activate the telomerase activity in 
the infected host cells 228. This scenario is actually supported by studies from various viruses. 
The HPV E6 and E7 proteins together promote the cooperative binding of Sp1 and c-Myc to 
the promoter region of hTERT and transcriptionally enhance its activity. The interaction 
between E6 and cellular E3-ligase E6AP is also required for this process 229 230. The EBV 
encoded latent membrane protein-1 (LMP1) is a functional homologue of tumor necrosis 
factor receptor (TNFR), which could constitutively stimulate hTERT transcription via 
activation of NF-kB and JAK/STAT pathways 231 232. 
Conversely, some viral proteins have been suggested to have a suppressor effect on 
telomerase as well. For instance, the HPV E2 protein down regulates hTERT transcription by 
interfering Sp1 activity 233. Additionally, the EBV LMP2A inhibits telomerase in a 
mechanism that is not fully understood yet, though its N-terminus immunoreceptor tyrosine-
based activation motif (ITAM) function seems to be required 93. 
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Interestingly, infection with tumor viruses not only prevent telomere erosion, but it is also 
associated with frequent occurrence of telomere dysfunction, which could further induce 
genomic instability 234. These abnormalities could be generated through distinct mechanisms 
after infection, such as: i) rapid cell proliferation without simultaneously activating telomere 
maintaining mechanisms; ii) expressing viral proteins that could disturb telomeric protein 
binding directly; iii) virus promoted reactive oxygen species (ROS) accumulation that could 
induce oxidative damage at telomere region; and iv) integration of viral genome into host 
telomeric DNA. For example, it has been shown earlier that EBV infected primary B-cells 
and EBNA1 expressing B-lymphoma cells are suffering from high levels of telomere 
dysfunction and genomic instability. Formation of TIFs and displacement of TRF2 from 
telomeres are frequently observed as well 235 236. A possible explanation for these could be 
the EBNA1-mediated binding of TRF2, RAP1 and tankyrase (telomere-associated poly-ADP 
ribose polymerase) at OriP, which further regulate the viral episome maintenance and 
replication, though it is not determined yet how these events could affect the shelterin 
complex function 237 238 239. Nevertheless, we have reported that EBNA1 induces the 
accumulation of intracellular ROS via transcriptional activation of the catalytic subunit of the 
NADPH oxidase NOX2. This is accompanied with high levels of DNA damage, telomere 
abnormalities and chromosomal instability 55.  
The frequent occurrence of telomere dysfunction seems to be an early event during infection 
relative to the increase in telomerase activity, indicating that an alternative mechanism could 
explain this phenomenon. Indeed, the work presented in this thesis indicates that ALT might 
be activated during early stage of tumor virus induced cell transformation. Thus, this 
hypothesis is consistent with improper protection of telomere, extrachromosome telomeres 
and formation of telomere associated DNA damage foci observed in the early stages of 
infection. Emerging signs for ALT activation were actually observed in the context of EBV 
freshly infected B cells and EBNA1 expressing B-lymphoma cells 236, KSHV vGPCR 
immortalized human umbilical vein endothelial cells, and HPV E6 or E7 immortalized 
human embryonic fibroblasts 240 241. And sometimes various ALT markers were shown to co-
exist with elevated telomerase activity as well 242. 
Thus, tumor viruses utilize both telomerase activity elevation and ALT activation strategies to 
evade replicative senescence. We propose a scenario where ALT activation during the early 
transformation period promotes high levels of telomere dysfunction and chromosome 
instability. Cells that would survive these events might acquire genetic alterations that could 
favor viral transformation. Survival and proliferation of these selected cells can further 
benefit from the increased telomerase activity, observed in later stages post-infection, which 
could further contribute to tumor progression by attenuating level of genomic instability.  
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2.4 OXIDATIVE STRESS  
Oxidative stress is an important biomarker for several diseases, including neurodegenerative 
diseases, cardiovascular diseases, aging-related development of cancer, and infectious 
diseases. While redox homeostasis is essential for the optimal function of cellular processes, 
malignant cells are often characterized by chronic oxidative stress, which is caused by 
imbalance between the generation and elimination of reactive oxygen species (ROS). 
2.4.1 Reactive oxygen species  
ROS are chemically reactive oxygen-containing molecules due to the presence of unpaired 
electrons. These include highly reactive radicals like superoxide anion (O2•–) and hydroxyl 
radical (HO•), as well as non-radical molecules such as hydrogen peroxide (H2O2) 243 244 245. 
These molecules are continuously produced during oxygen consumption in metabolic 
reactions that mainly occur in mitochondria 246 247, peroxisomes 248 and endoplasmic 
reticulum 249, as well as through enzymatic reactions that involve NADPH oxidase, xanthine 
oxidase, lipoxygenase and cylooxgenase 250 251 252 253. Superoxide anions are considered to be 
the primary ROS product from both mitochondrial electron transport chain complexes and 
oxidases reactions. It is estimated that about 2% of the total oxygen consumed in 
mitochondria is converted to form superoxide anions, therefore mitochondria are considered 
to be a major source of ROS 246 247. After releasing into the cytoplasm, superoxide dismutases 
(SODs) are responsible for converting them into hydrogen peroxide 254 255, which is further 
converted to water by catalase and glutathione peroxidase 245 256. Hydrogen peroxide may be 
further converted to highly reactive product hydroxyl radicals through the Fenton reaction, 
where election transition metal ions like Fe2+ serve as catalyzers 257 258 259. 
Since different levels of ROS can induce distinct biological responses, tight regulation of 
both ROS promoting and scavenging pathways is required 260 261. Under physiology condition, 
ROS act as messenger molecules that sustain essential cell signaling, and activate the cellular 
responses to stress. For example, intracellular ROS were shown to promote cell proliferation 
and migration, and induce pro-inflammatory cytokine secretion 262 263 264. However, excess 
levels of ROS could damage cell structures like lipids, proteins and DNA, activate oncogenic 
signaling pathways, trigger cell senescence, or cause mitochondria failure that results in 
release of cytochrome c and apoptosis 265 266. The effects of excessive ROS production are 
normally balanced by enzymatic and non-enzymatic cellular antioxidants. The most efficient 
enzymatic antioxidants are superoxide dismutase, catalase and glutathione peroxidase 267 256, 
while the non-enzymatic antioxidants include vitamin C, vitamin E, glutathione and 
thioredoxin (TRX) 268 269 270. These molecules cooperate in reducing the overproduced ROS 
to prevent irreparable cellular damage. 
2.4.2 Oxidative stress and tumorigenesis  
Tumor cells are commonly under oxidative stress, probably due to the aberrant metabolism 
induced by oncogene activation. Although the contribution of oxidative stress to malignant 
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transformation is still controversial, it is implicated during all stages of tumorigenesis 
including initiation, promotion and progression 271. 
The initiation stage involves non-lethal but irreversible mutations of DNA, where ROS-
induced oxidative DNA damage is one of the common contributors. The majority of the cells 
will be arrested by the DNA damage response, but some cells may keep dividing in spite of 
mutations, thus representing the initiated cells. The promotion stage is experimentally defined 
as clonal expansion of the initiated cells, where cell proliferation is enhanced and apoptosis is 
inhibited. This stage is a reversible process during which ROS contribute to altered gene 
expression and therefore modified signal transduction. The outcome of the promotion phase 
is the formation of focal lesions where the expanded cells reach a pre-neoplastic state. During 
the final progression stage, accumulation of more irreversible genomic alterations is achieved, 
leading to transition of expanded pre-neoplastic cells to more aggressive malignant cells. 
Genomic instability, loss of chromosome integrity and functionally inhibited tumor 
suppressors are the features of this process, where oxidative stress could further enhance 
these aberrations 272. 
Cancer cells are characterized by abnormal metabolism and protein synthesis, which results 
in chronic oxidative stress. However, cellular antioxidant responses are commonly increased 
in malignant cells through mutations and activated oncogenes, which allows escape from cell 
death. Thus, under condition of moderate ROS levels, cancer cells may acquire additional 
mutations that further drive tumorigenesis. Hence, the antioxidant capacity of tumor cells 
could be considered as a potential therapeutic target 273 (Figure 4). 
 
Figure 4. Interplay between ROS level and cancer (modified from Cairns et al, 2011). Low levels of ROS are beneficial 
for cell proliferation and survival, while high levels of ROS trigger senescence and cell death. In cancer cells, aberrant 
metabolism and protein synthesis promote high levels of ROS. While adapted mutations and altered gene expressions enable 
the cancer cells to exert cellular antioxidants for reducing ROS levels toward moderate levels. On one hand, this tight control 
of redox allows the cancer cells to avoid the detrimental fate of high levels of ROS. On the other hand, it also increases the 
chance of these cells to acquire more ROS-mediated mutations.    
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2.4.3 Tumor viruses and oxidative stress  
Oxidative stress is often observed during infection by various tumor viruses, and recent 
studies have started to elucidate its role in the context of virus-induced transformation. 
Elevated ROS production has been reported following binding and entry of EBV, KSHV, and 
HSV1 274 275 276 277 278. For example, within two hours of infection, EBV induces oxidative 
stress with decreased levels of different cellular antioxidants including SODs and catalase 274. 
ROS are also produced early after KSHV infection where they promote efficient entry of the 
virus into endothelial cells by regulating macro-pinocytosis 275. The early ROS production 
was initially explained by the activation of phagocytes, which represents a non-specific 
immune response to eliminate the pathogens 279. However, binding of the virus appears to be 
required to trigger ROS production, since pretreatment of KSHV with heparin abolishes it 275. 
Multiple viral products contribute to the establishment of oxidative stress during both latent 
and productive infection. The EBV latent protein EBNA1 promotes ROS production in BL 
cells via transcriptional activation of the catalytic subunit of the NADPH oxidase NOX2, 
which is associated with DNA damage and genomic instability 55 56. Additionally, the EBV 
latent product LMP1 was shown to promote the accumulation of ROS in NPC by up-
regulating the NADPH oxidase subunit p22phox via activation of JNK signaling, which may 
result in increased oxygen consumption, hypoxia and enhanced glycolysis 280. Likewise, the 
KSHV glycoprotein K1 induces elevation of intracellular ROS through upregulation of Rho-
like small GTPase Rac1, which activates the NADPH oxidase. High levels of ROS enhance 
vascular permeability, which alters the tumor microenvironment 281. The early protein of 
KSHV vGPCR also induces ROS via the same mechanism, while quenching of ROS by 
treatment with NAC leads to impaired tumor angiogenesis and proliferation 282. Furthermore, 
the cellular redox master regulator NRF2 is activated during KSHV infection of endothelial 
cells, which suggests that a precise modulation of the oxidative status is crucial for viral 
oncogenesis 283 284.  
 
2.5 SIGNALING BY POST-TRANSLATIONAL MODIFICATIONS  
Due to limited genome size, tumor viruses need to rely on the host cell machinery for almost 
every single step of their life cycle, including virus entry, proliferation initiation, viral 
genome replication, virion packaging and egress. In addition, viruses also need to overcome 
the host immune responses in order to survive in the infected cells. One strategy by which 
viruses may use their limited genetic information to achieve a broad remodeling of the 
cellular environment is by interfering with protein post-translational modifications (PTMs). 
PTMs involve the addition of chemical residues, such as phosphate, glycan, methyl and 
acetyl groups, or small polypeptides, which changes the conformation, stability, interaction 
properties, subcellular localization and ultimately the function of the substrate. Ubiquitin (Ub) 
and ubiquitin-like (UbL) proteins, such as the small ubiquitin-related modifier (SUMO), the 
multiple neural precursor cell-expressed developmentally down-regulated 8 (NEDD8), and 
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the interferon-stimulated gene 15 (ISG15), are small polypeptides modifiers that share 
structural similarities 285 286. Cellular signaling pathways and functions that are regulated by 
this type of post-translational modification include transcription, protein trafficking and 
degradation, signal transduction, DNA replication, DNA damage repair and apoptosis 286 287. 
2.5.1 The Ub/UbL modification cascade  
The conjugation of Ub and UbLs to protein substrates is a multistep process where three 
enzymes are sequentially involved 288. First, the modifiers are activated by an activating 
enzyme (E1) through formation of a thiolester bond between their C-terminal glycine and a 
cysteine residue in the E1, where ATP hydrolysis is also required. Then, the activated 
modifiers are transferred to the catalytic cysteine residue of a conjugating enzyme (E2). 
Finally, a ligase (E3) catalyzes the transfer of the modifier from the E2 to a lysine residue of 
the substrate 289. Once the first Ub or UbL is attached to the target, this process can be 
repeated by adding a new modifier to the previous one, resulting in the formation of a poly-
modifier chain. Depending on the modifier, one or two E1, a limited number of E2 and a 
great number of E3 have been identified 290. The number of E3s guarantees the specificity of 
substrate recognition and the types of conjugation.  
The E3 ligases can be divided into three major groups depending on their structure and 
ubiquitination mechanisms: the HECT (Homologue of E6-AP C-terminus) domain 
containing ligases, the RING (Really Interesting New Gene) domain containing ligases and 
the U-box ligases 291 292 293. The RING domain containing E3s constitute the largest ligase 
family that regulates various cellular events including DNA replication, cell proliferation, cell 
cycle progression and apoptosis 294. The major family of the RING domain-containing ligases 
is the Cullin-RING ligases (CRLs), where a multi-protein complex is assembled around the 
NEDD8 conjugated cullins. This complex serves as a scaffold that binds to E2 via its RING 
domain and to substrate with an adaptor protein, which facilitates the transfer of ubiquitin 
from the E2 to the substrate 295 296. 
The Ub and UbLs are synthesized as inactive precursors and specific proteases are required to 
cleave their C-termini in order to expose the terminal glycine. This process is managed by 
specific deconjugating enzymes called deubiquitinating enzymes (DUBs) and UbL-specific 
proteases (ULPs). DUBs and ULPs also can hydrolyze the covalent bond that link the 
modifiers to their substrates, which reverse the signal and maintain a constant intracellular 
pool of free Ub and UbLs 297. Approximately 100 DUBs are encoded by the human genome. 
They can be categorized into five families: the ubiquitin specific proteases (USPs), the 
ubiquitin C-terminal hydrolases (UCHLs), the ovarian tumor related proteases (OTUs), the 
Machado-Joseph disease proteases (MJDs) and the Jab1/MPN/Mov34 domain containing 
metalloenzymes (JAMM) 297. The human ULPs are represented by the sentrin specific 
peptidases (SENPs). All DUBs and ULPs are cysteine proteases except for the JAMMs that 
cleave the modifiers from substrate in a Zinc ion and ATP dependent manner 297 298. 
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Different types of ubiquitin modification are known. These modifications include 
monoubiquitination, multiubiquitination where monoubiquitination occurs at multiple 
substrate sites, and polyubiquitination where Ubs are sequentially added onto each other on 
the substrate. Monoubiquitination can regulate DNA damage repair, histone function, gene 
expression and receptor endocytosis 299 300 301 302 303, while multiubiquitination mainly 
modulates receptor endocytosis 304. Additionally, poly-ubiquitin chains can be formed on 
each of seven Lysine (K) residues of ubiquitin molecule, including K6, K11, K27, K29, K33, 
K48 and K63 305. The length and linkage structure of the chain will further determine the fate 
of substrates and their interaction with different cellular function proteins 306. For example, 
K48 linked Ub chains are the most abundant type in human, which mediate the proteasome 
degradation of various substrates 305. Additionally, the K63 Ub chains are also well 
characterized modifications involved in non-proteolytic cellular functions such as 
intracellular trafficking, autophagy, DNA damage response and cell signaling transduction 306 
307 (Figure 5). On the other hand, UbLs also contain multiple lysines but the types and the 
fates of different UbLs chains are still largely unknown. For example, while mono- or poly-
SUMO chains have been identified the only defined NEDD8 modification is the 
mononeddylation of the CRLs. 
 
Figure 5. The Ub/UbL system. Inactive precursors of Ub and UbLs need to be processed by DUBs or ULPs to expose their 
terminal glycines for conjugation. Throughout the enzymatic cascade that involves activating enzyme E1, conjugating 
enzyme E2s and substrate ligase E3s, Ub and UbL modifiers are evantually linked to specific substrates. These modifications 
result in both non-proteolytic and proteolytic cellular functions. Afterwards, substrates linked modifiers are deconjugated by 
DUBs or ULPs for recycling. 
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2.5.2 Viruses interfere with the Ub/UbL pathway  
Due to the versatility of Ub and UbL signaling in regulating protein functions, it is not 
surprising that viruses have evolved mechanisms to mimic, inhibit or redirect the activities of 
the Ub and UbL signaling cascade 290 308. Two general strategies are used by viruses to 
interfere with this system. Viruses may either encode adaptor proteins that hijack the cellular 
enzymes to target their own favored substrates, or they may encode homologues of the 
cellular enzymes with distinct structure and substrate specificity. 
Virus-encoded E3 ligases are normally found in large DNA viruses. For example, the KSHV 
encoded protein K3 and K5 regulate the expression of the major histocompatibility complex 
(MHC) class I molecules by acting as ubiquitin E3 ligases. The N-terminal domain of K3 and 
K5 add a K63-linked ubiquitin chain to MHC I molecules, therefore promote endosomal 
sorting and further lysosome degradation 309 310 311. In this way, KSHV decreases antigen 
presentation and manages to escape from cytotoxic T-lymphocyte recognition.  
Viruses encoded adaptor proteins recruit or redirect cellular E3 ligases. A classic example of 
this strategy is the HPV E6 protein that reprograms the cellular E3 ligase to promote 
proteasome-dependent degradation of p53 162. The EBV membrane protein LMP2A also acts 
as an E3 adaptor that redirects the cellular NEDD4 ligase for proteasome-dependent 
degradation of tyrosine kinases Lyn and Syk, which inhibits triggering of the productive virus 
cycle by preventing the activation of BZLF1 upon engagement of the B-cell receptor 312 313. 
Viruses also encode functional homologs of Ub/UbL deconjugases. A particularly interesting 
example is the family of deconjugases encoded by the large tegument proteins of 
herpesviruses. The EBV encoded member of this family, BPLF1, was shown to promote the 
production of infectious virions by deubiquitinating the proliferating cell nuclear antigen 
(PCNA), the E3 ligase Rad18 and the viral ribonucleotide reductase 314 315 316. BPLF1 was 
also shown to deubiquitinate TRAF6, which my favor virus production by inhibiting NF-kB 
signaling and β-interferon production 120 119. Moreover, BPLF1 and other member for this 
enzyme family exhibit a NEDD8-specific deconjugase activity, which regulates the activity 
of cellular Cullin-RING ubiquitin ligases (CRLs) and promotes efficient viral DNA 
replication 118 317. 
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3 AIMS OF THIS THESIS 
 
The overall aim of this thesis was to uncover the complexity of virus and host interactions 
during EBV infection. In particular we wished to assess how EBV could adapt to and exploit 
cellular responses to establish an environment conducive to B-cell immortalization and 
productive infection, respectively. To this end, my colleagues and I have addressed the 
following specific aims: 
 
1. Investigate the mechanisms that rescue EBV infected B cells from replicative senescence 
during early phases of transformation. 
 2. Identify the key factors that limit the efficiency of EBV induced B-cell transformation 
during early stage of infection. 
3. Elucidate the machineries by which EBV remodels cellular environment to maintain 
successful productive infection. 
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4 METHODOLOGY 
 
A complete description of the experiment procedures used in this thesis is available in the 
appended articles. In this section I will briefly discuss the features and principles of chosen 
experimental methodologies.  
 
4.1 TELOMERE ANALYSIS BY FISH BASED TECHNIQUES 
Q-FISH: Quantitative fluorescence in situ hybridization (Q-FISH) was used as a method of 
choice to examine the size and status of individual telomeres. A more traditional way for 
measuring telomere size is southern blot that uses restriction endonuclease for cleavage of 
genomic DNA at sub-telomeric sites to create terminal restriction fragments (TRFs) 318. The 
fragmented DNA is then gel electrophoresed, transferred to membrane, hybridized with 
labeled probes recognizing telomere sequences and visualized by chemiluminescence. 
Southern blot provides an estimation of the telomere size of entire cell population without 
specific information on individual telomeres. In contrast, labeling of individual telomeres by 
Q-FISH allows direct assessment of the size of individual telomeres with similar or even 
better sensitivity of southern blot 319. The peptide nucleic acid (PNA) is a synthetic DNA 
probe that hybridizes to target telomere sequences with specificity, high affinity, stability and 
low background 320 321. In addition, Q-FISH offers the additional advantage of allowing direct 
analysis of a small subpopulation of proliferating cells, avoids possible artifacts due to the 
presence of infrequent numbers of non-proliferating or dead cells upon EBV infection. By Q-
FISH we could also visualize telomere abnormalities such as absence of telomere signals, 
telomere fusion and extra-chromosome telomere.  
CO-FISH: Telomere-sister chromatid exchange (T-SCE), which is the outcome of HR 
dependent repair at telomeres, can be detected with a FISH based technique known as 
chromosome orientation FISH (CO-FISH). The cells were first cultured in the medium 
containing Bromodeoxyuridine (BrdU) and Bromodeoxycytidine (BrdC), which are synthetic 
nucleotides analogue of thymidine and cytidine, for a single cell cycle. Then the 
complementary telomeric DNA was removed by UV exposure and exonuclease III digestion, 
followed by sequential hybridization with Cy3-TelG and FITC-TelC specific probes that 
target lagging G-rich and leading C-rich telomere strand respectively. After microscopy 
analysis, sister chromatin exchange was scored by the presence of chromosomes with both 
TelG and TelC probe signals at telomeres of both sister chromatids. 
IF-FISH: Accumulation of PML nuclear bodies (PNBs) containing telomeric DNA, known 
as ALT-associated PNBs (APBs), is a characteristic feature of ongoing homologous 
recombination repair at telomeres. TRF2 is an important shelterin complex component 
involved in telomere protection, where displacement of TRF2 at telomeres could lead to 
aberrant activation of HR. Combination of specific immunofluorescence with in situ 
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hybridization (IF-FISH) provides a direct and specific method for detection of proteins that 
are associated with telomere sequences, such as PML and TRF2. Immunofluorescence (IF) is 
performed prior to fluorescence in situ hybridization (FISH) in this method. The presence of 
APBs was scored in images captured by confocal microscope based on colocalization of 
PNBs and telomere signals on a single focal plane. For quantification of telomere associated 
TRF2, images were acquired and analyzed with a ImageXpress Micro device. Two thousand 
telomere signals were analyzed from different images for each condition and the intensity of 
TRF2 and telomeres fluorescence within each telomere signal was quantified. 
 
4.2 DETECTION OF TELOMERASE ACTIVITY BY TRAP ASSAY  
Telomerase is a ribonucleoprotein that adds telomeric repeats to the 3’ end of telomeres using 
its RNA template. The telomeric repeat amplification protocol (TRAP) is a sensitive and 
efficient PCR based assay for detection of telomerase activity. This assay is an improved 
version of original method described by Kim et al. 322, which reduced the amplification 
artifacts and magnified its detection sensitivity 323. Moreover, large scales of surveys on 
telomerase activity in various human cells and tissues have been carried out with this method 
324 197 325 326 327. The experimental procedure started from extraction of lysates containing 
telomerase, followed by extension of kit supplemented substrate oligonucleotide with 
telomerase, PCR amplification of extended products, separation of individual product by gel 
electrophoresis, gel staining and imaging, and analysis of the images with calculated total 
product generated (TPG) units. Cell lysates with confirmed telomerase activity were provided 
in the kit as standard control. Heat inactivated samples and lysate from the telomerase 
negative cell line U2OS were used as negative control. 
 
4.3 MEASUREMENT OF REACTIVE OXYGEN SPECIES   
All cells constantly produce ROS during aerobic metabolism, and oxidative stress occurs 
when the ROS generation overwhelms the cellular antioxidant capacity. The most 
straightforward technique for measuring cellular ROS levels uses cell permeable fluorescent 
and chemiluminescent probes, followed by flow cytometry analysis. The colorless 2,7-
dichlorodihydrofluorescein diacetate (H2DCF-DA), which is the non-fluorescent precursor of 
H2DCF, is one of the most widely used probes for direct measurement of ROS 328 329. 
Intracellular esterase cleaves H2DCF-DA at its two-ester bond producing the relatively 
impermeable form H2DCF. Upon oxidation, a highly fluorescent product DCF is yielded 
from its reduced form. The increased DCF fluorescence is then detected by flow cytometry, 
which reflects the redox status of samples. Dihydroethidium (DHE) may also be used as 
probe for r ROS detection. However, DHE is predominantly oxidized by superoxide anion, 
while H2DCF-DA indicates oxidation by hydrogen peroxide, peroxynitrite, hydroxyl radical 
and also superoxide anion though at a lesser degree. Thus, we used H2DCF-DA in our 
experiments for broader detection of intracellular ROS. 
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4.4 MEASUREMENT OF CELL DIVISIONS   
Carboxyfluorescein diacetate, succinimidyl ester (CFSE) serves as a cell-retained tracing 
reagent. CFSE can diffuse into the cells and it is colorless and non-fluorescent until the 
acetate groups are cleaved by intracellular esterase. The carboxyfluorescein succinimidyl 
ester becomes highly fluorescent and its succinimidyl ester reacts with intracellular amines, 
forming conjugates that are very well retained in cells. Unconjugated CFSE diffuses back to 
the extracellular medium can be washed away. Combined with flow cytometry analysis, 
CFSE incorporation provides a convenient method for monitoring cell division. CFSE was 
incorporated into freshly isolated B cells prior to both mitogen stimulation and EBV infection, 
and cell division was traced until 10 days of culture. Individual cell division peaks were then 
identified by 50% fluorescence decrease, and the mean division number of total cell 
population was calculated as (sum of % of cells in each peak x number of cell divisions)/100. 
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5 RESULTS AND DISCUSSIONS 
 
At the time the work described in this thesis was initiated the accepted scenario of EBV 
pathogenesis suggested a clear distinction between the capacity of the virus to promote the 
autonomous proliferation of latently infected but virtually normal B-lymphocytes, which 
could give rise to life-threatening lymphoproliferations when the host immune defenses are 
severely compromised, and its involvement as a promoting factor in “true” malignancies that 
are driven by distinct virus-independent genetic alterations. This view was challenged by 
several observations suggesting a more direct role of the virus as an initiating factor of 
malignancy. In particular, cytogenetic studies performed in EBV negative and positive B-
lymphoma lines suggested that virus carriage is associated with the establishment of an 
oxidative environment and with the induction of chromosomal instability, DNA damage, 
activation of the DNA damage response, telomere dysfunction and activation of ALT 55 330 171 
56. Chromosomal aberrations were also observed in freshly infected normal B-cells already 
within the first weeks after growth transformation followed by the establishment of 
monoclonal cultures 235, suggesting that virus carriage may promote the occurrence of 
random genetic alterations that provide a selective growth advantage. Furthermore, the early 
proliferative response of EBV infected normal B lymphocytes was shown to be accompanied 
by the occurrence of extensive DNA damage 37, suggesting that viral products may be 
directly involved in the establishment of a mutator phenotype that could promote malignancy. 
The work described in this thesis aimed to critically assess these possibilities by performing a 
detailed analysis of the early cellular response to EBV infection (Papers I and II). 
The EBV transforming capacity can be exerted only if the virus can establish a successful 
infection, and this could be achieved by counteracting or exploiting the cell intrinsic and 
innate immune defense. Thus in Paper III, we have assessed how viral products that are 
delivered to the infected cells together with the incoming virion, modulate these cellular 
functions. 
 
5.1 EBV-INDUCED B-CELL PROLIFERATION IS ACCOMPANIED BY 
TELOMERE DYSFUNCTION AND ACTIVATION OF ALT (PAPER I) 
Telomere dysfunction and chromosomal instability are hallmarks of cancer 331. EBV-positive 
BL cell-lines exhibit significantly more chromosomal instability compared to their EBV 
negative counterparts and this is associated with multiple signs of telomere dysfunction and 
activation of ALT 56. Since the observation was made in established long term cultured cell 
lines, it may be argued that the effect is dependent on inherent properties of the malignant 
cells and facilitated by the long-term culture conditions. Thus, the primary goal of this work 
was to assess whether this EBV-driven phenotype is also observed in freshly infected normal 
B cells.  
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To address this possibility we first compared the occurrence of telomere abnormalities in 
metaphase chromosomes from EBV-infected B-lymphocytes. As a control we used B- or T-
cell blasts where proliferation was driven by mitogenic stimulation rather than EBV 
immortalization. In spite of comparable levels of cell proliferation, the EBV infected cells 
showed a high prevalence of chromosomes with abnormal telomeres, usually loss or 
duplication of telomere signals and telomere fusion. By day 7 between 50-60% of the 
metaphases of EBV infected cells contained one or more chromosomes with abnormal 
telomeres. Extra-chromosomal telomere signals were also frequently detected, indicating 
double strand breaks of telomeric DNA. Proliferation of the EBV-infected B lymphocytes 
was associated with a significant increase of the intensity of the telomere signals, as assessed 
by FISH analysis of metaphase plates already after 2 weeks of culture while the signal 
intensity remained constant or was decreased in the mitogen blasts. Most importantly, the 
infected cells exhibited highly heterogeneous signal intensity, with a strongest:weakest signal 
ratio exceeding 50 fold. These data indicate that EBV infection induces telomere elongation. 
However, this effect was not due to an increased telomerase activity, since TRAP assays 
revealed a very low activity in both EBV- and mitogen-induced blasts, suggesting that EBV 
infection promotes an alternative mechanism to ensure telomere elongation. 
As summarized in the introduction, the accumulation of extra-chromosomal telomeres and 
increased telomere length in the absence of telomerase activity are indicative for the 
activation of ALT 201. Recognized markers of ALT are the accumulation of PML nuclear 
bodies containing telomeric DNA known as ALT-associated PNBs (APBs) 204. In addition to 
PML, APBs contain a variety of proteins involved in the DNA damage response (DDR), and 
polymerases that use sister chromatids or extra-chromosomal telomeric sequences as 
templates for telomere extension 205 206. We found that APBs are regularly detected in EBV 
infected cells already after 3 days of infection while they are virtually absent in mitogen-
induced blasts. This was accompanied by the occurrence of telomere sister chromatid 
exchange (T-SCE) measured by chromosome orientation (CO)-FISH. This series of 
experiments confirmed that the early phases of B-cell immortalization is accompanied by 
telomeric DNA damage, and the activation of recombination-based mechanisms of repair 
may assure the maintenance of telomere homeostasis in rapidly proliferating cells with low or 
absent telomerase activity.  
Telomere de-protection is a common cause of DNA damage at telomeres 332. In order to 
assess whether uncapping might explain the telomere dysfunction phenotype induced by 
EBV infection, the functionality of the shelterin complex was investigated by monitoring the 
co-localization of telomeres with the DNA binding subunit TRF2 in IF-FISH assays. We 
found that telomeres lacking co-localized TRF2 signals are frequent in the interphase nuclei 
of EBV-infected cells. To assess whether this may correlate with defects in the expression of 
TRF2 or other proteins involved in the maintenance of telomere structure, the expression of 
the shelterin subunits TRF1, TRF2 and POT1, and the ATRX subunit of the ATRX/DAXX 
chromatin remodeler were compared in western blots. We found that the proteins are 
expressed at comparable levels in mitogens and EBV induced blasts suggesting that the 
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telomere de-protection observed in infected cells is not primarily due to selective loss of the 
shelterin or ATRX/DAXX complexes. 
The evasion of proliferative senescence is a key event in viral oncogenesis. Many tumor 
viruses, most notably KSHV, HPV, HCV and HTLV1, achieve this goal by regulating the 
activity of telomerase, which maintains the length of telomeres and ensures proliferative 
immortality 333. EBV infected cells may adopt an alternative strategy for maintenance of 
telomere homeostasis based on the activation of homologous recombination. 
An interesting question is why EBV would use a different strategy to maintain telomere 
homeostasis. Our laboratory has previously shown that EBNA1 promotes genomic instability 
and telomere dysfunction in BL cells by transcriptional activation of the catalytic subunit of 
the NADPH oxidase, NOX2, resulting in increased intracellular levels of ROS 55. It is 
possible that EBNA1 exerts a similar effect also in primary infected B-lymphocytes. The 
oxidative environment may directly affect the function of the shelterin and ATRX/DAXX 
complexes since oxidation disrupts the recognition of telomeric DNA by TRF1 and TRF2 334. 
This effect, possibly associated with the inability of EBV to up-regulate TRF1, TRF2, POT1 
and ATRX in newly infected cells, may explain why a significant proportion of the telomeres 
has little or no associated TRF2 in spite of unchanged levels of TRF2 detected in western 
blot. 
The enhanced recombination rate observed at telomeres of EBV infected cells may also 
depend on the high sensitivity to oxidative-mediated DNA damage of the telomeric G-triplet. 
This effect increases the frequency of S1 nuclease sensitive sites at telomeres and could 
promote the activation of recombination-based repair 335. Therefore, the oxidative damage-
induced telomere deprotection may result in activation of DNA repair pathways and ALT-
mediated telomere elongation and/or telomere abnormalities, in absence of increased 
telomerase activity, allowing EBV-infected cells to overcome replicative senescence during 
the early stages of infection.  
This scenario differs from the situation observed in long-term-established LCLs, which are 
characterized by increased telomerase activity and enhanced levels of the shelterin proteins 
TRF1, TRF2, POT1 and ATRX. Most likely this mechanism is associated with lower levels 
of genomic instability that would ensure a higher rate of cells survival. 
 
5.2 EBV INFECTION INDUCES OXIDATIVE STRESS THAT IS REQUIRED FOR 
B-CELL IMMORTALIZATION (PAPER II) 
To address whether early stages of infection are associated with induction of an oxidative 
environment as suggested in Paper I, we compared the levels of ROS over time by H2DCF-
DA fluorescence in freshly infected normal B-lymphocytes and mitogen stimulated cells. A 
peak of fluorescence was observed in both mitogen stimulated and EBV infected cells after 
culture for 24 hr. However, while this was followed by a rapid return to baseline levels in 
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mitogen-stimulated cells, a steady increase was observed in EBV-infected cells followed by 
stabilization at levels comparable to those detected in LCL cells. As predicted from the 
discussion of Paper I, this oxidative environment promoted induction of single and double 
stand DNA breaks, detected by γ-H2AX staining. EBV infection caused a striking increase of 
γ-H2AX foci in the nuclei of EBV-infected cells whereas significantly fewer mitogen-
stimulated cells were γ-H2AX positive and the nuclei exhibited fewer and smaller foci. The 
accumulation of ROS correlated with up-regulation of NOX2, while treatment with ROS 
scavengers reduced the percentage of γ-H2AX positive cells and fluorescence signals to the 
levels observed in mitogen-induced blasts.  
Induction of DNA damage in infected cells was previously reported. It has been proposed 
that the activation of c-Myc by EBNA2 may generate hyperproliferation-associated 
replicative stress and give rise to large numbers of DNA double-strand breaks that trigger the 
cellular DDR and halt cell growth until a balance favoring long-term proliferation is achieved 
through the activity of viral products that slow-down cell proliferation and inhibit the DDR 37. 
Our data proposes a different scenario, where oxidative stress appears to be the main cause of 
DNA damage during the early phase of EBV induced B-cell growth transformation.  
While the induction of ROS provides a satisfactory explanation for the capacity of EBV 
infection to induce DNA damage and might also explain the relative inefficiency of 
transformation, the purpose of this effect is unclear. To address this question, freshly infected 
cells were cultured in medium supplemented with ROS scavengers. Surprisingly, while the 
addition of NACA had no appreciable effect on the proliferation of mitogen-stimulated cells, 
it virtually abolished cell proliferation of EBV-infected cells. This was neither due to 
decreased virus load, nor to significant differences in the levels of viral transcripts that are 
expressed during the initial phase of infection. However, monitoring of protein expression by 
immunofluorescence and western blot revealed a significant decrease of LMP1. Thus, the 
majority of EBNA2 positive cells in the NACA treated cultures expressed low or 
undetectable levels of LMP1 and the intensity of the LMP1 specific band detected in western 
blots was significantly decreased.  
Quenching the intracellular levels of ROS by NACA treatment also promoted a significantly 
decrease of the cellular transcription factor STAT3, and almost complete disappearance of its 
phosphorylated form. Similar results were obtained by treatment with the STAT3 specific 
small molecule inhibitor Stattic that prevents STAT3 phosphorylation.336. This indicates that 
the viral-induced oxidative stress promotes STAT3 activation, which was previously shown 
to play a key role in EBV-induced transformation 337,338. Stattic treatment inhibited EBV-
induced cell proliferation but did not affect LMP1 expression, suggesting that, although both 
proteins are ROS regulated and are essential for immortalization, they act independently. 
The effect of LMP1 can mimic survival signals that are normally delivered to antigen-
stimulated B cells by the T helper lymphocytes 339. Indeed, LMP1 regulates the activity of 
cellular signaling pathways, such as the NF-κB and MAPK pathways that control B-cell 
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proliferation, up-regulates the expression of anti-apoptotic proteins, such as the cellular A20, 
and promotes downregulation of the ATR kinase, which hampers the DDR 80 79 81 83 87 85. 
Conversely, the ROS-dependent STAT3 pathway may mirror the proliferative and survival 
effect provided by the T helper secreted cytokines 340. The effect of ROS on this transcription 
factor is likely to be mediated by oxidative inactivation of specific phosphatases 341. 
Interestingly, while treatment with ROS scavengers drastically decrease the efficiency of 
transformation, quenching of ROS affected only marginally the proliferation of established 
LCLs and did not alter the expression of LMP1 though the phosphorylation of STAT3 was 
still inhibited. Thus, the effect of ROS on these signaling pathways, and their contribution to 
cell growth appear to be different in different phases of the infection.  
Since LMP1 mRNA levels and protein turnover were not affected, we surmised that ROS 
might regulate LMP1 mRNA translation, since several cellular and viral miRNAs are known 
to target this transcript 110,342,343, and oxidative stress-dependent alterations of miR profiles 
have been reported in a variety of different tissues and pathologic conditions 344. Cellular 
miRs of the miR-17/20/106 family and several EBV BART miRs were shown to target the 
LMP1 3’UTR 110,342,343,345. We found that quenching of ROS is accompanied by a 
reproducible increase of miR-BART1-5p and miR-BART3-5p. 
Although the effect on each miR was relatively small, a physiologically relevant level of 
inhibition is likely to be achieved by the combined action of several miRs targeting the same 
mRNA. The ROS-dependent inhibition of BART miRs during the early phase of infection 
has interesting implications for the dynamics of the transformation process. These miRNAs 
are expressed in LCLs and in EBV-associated malignancies where targeting of LMP1 
promotes cell survival by dampening the toxic effects of LMP1 overexpression 346. However, 
during the early stage of infection when the transcripts are less abundant, high levels of the 
miRs could keep the amount of protein below the threshold required for activation of the 
signaling cascades that promote efficient cell proliferation and survival.  
The results presented in Paper II highlight a previously unrecognized role of oxidative stress 
in EBV-induced B-cell transformation via regulation of viral and cellular proteins that control 
signal transduction and cell proliferation. Although the association between EBV infection 
and oxidative stress was observed before, the contribution of ROS to the establishment of 
EBV latency was not explored. We found that, in spite of causing significant DNA damage, 
the initial accumulation of high levels of ROS is essential for B-cell immortalization by 
modulating two key molecules: the viral protein LMP1 and the cellular transcription factor 
STAT3, possibly mirroring the normal pathway of antigen-induced B cell activation. 
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5.3 CLEAVAGE BY CASPASE-1 TARGETS THE EBV DECONJUGASE TO THE 
NUCLEUS OF THE INFECTED CELLS (PAPER III) 
Viral-induced modulation of the cellular microenvironment is essential for viral DNA 
synthesis and for the regulation of acute, chronic and latent infections 347. Post-translation 
modification of proteins by covalent linkage of ubiquitin UbLs, such as SUMO, NEDD8, 
ISG15, regulates diverse cellular processes, including the cell cycle, DNA repair, 
transcription, signal transduction and immune responses 348,349. Thus, one efficient viral 
strategy for interference with this regulatory system, leading to a wide remodeling of the 
cellular environment, is the expression of homologs of cellular ligases and deconjugases 290. 
These viral enzymes are often multifunctional proteins that share little homology with their 
cellular counterparts and are therefore attractive targets for selective inhibition. The EBV 
encoded deconjugase, BPLF1, has very potent ubiquitin deconjugase activity in various 
experimental models. Ectopic expression of BPLF1 N-terminus promotes the dislocation of 
ubiquitinated ERAD substrates 350, and it is also associated with deubiquitination of the viral 
ribonucleotide reductase (RR) 315 and the cellular DNA polymerase processivity factor PCNA 
314, resulting in downregulation of the viral RR activity and attenuation of Polη at DNA 
damage sites. Furthermore, expression of the catalytically active BPLF1 was shown to 
correlate with deubiquitination of TRAF6 and inhibition of NF-kB signaling during 
productive infection 352. The enzyme is also a potent deneddylase that hydrolyzes NEDD8 
conjugates in vitro and stabilizes several CRL substrates in transfected cells. Expression of 
BPLF1 alone or in the context of the productive virus cycle induced the accumulation of the 
licensing factor CDT1 and arrest of the cells in S-phase. It is noteworthy that this tegument 
protein is incorporated in the virus particle and is delivered as a preformed viral product to 
the cytoplasm of newly infected cells. Thus, owing to its dual substrate specificity and 
expression during different phases of the infection, BPLF1 may target a broad variety of 
substrates and regulate different cellular functions, including the early anti-viral response. In 
this paper we have investigated the effect of BPLF1 on virus replication and revealed an 
unexpected contribution of cellular factors in the regulation of its activity. 
The Akata-Bx1 cell line was used to study the abundance of Ub and NEDD8 conjugates 
during the productive infection triggered by surface IgG cross-linking. While the levels of 
conjugated and free Ub remained virtually unchanged over time, the NEDD8 conjugates 
progressively decreased in parallel with the increase of free NEDD8. The effect was 
abrogated in cells expressing a BPLF1 specific shRNA, supporting the conclusion this 
endogenous enzyme acts as a deneddylase during virus replication. Induction of the 
productive virus cycle was accompanied by a gradual decrease of the Cul1, Cul3, Cul4A and 
Cul5 specific bands while Cul2 and the CRL subunit RBX1 were not affected. The nuclear 
and cytoplasmic abundance of Cul1, Cul2, Cul3, Cul4A and Cul5 was then monitored in the 
induced cells. Surprisingly, while nuclear Cul1, Cul3, Cul4A and Cul5 decreased, the amount 
of proteins detected in the cytoplasm remained unchanged. Cul2, which has an exclusively 
cytoplasmic localization, was not affected. These data indicate that only nuclear cullins are 
affected by the deneddylase activity of BLPF1. In line with this observation, induction of the 
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productive cycle was accompanied by the accumulation of several nuclear substrates of 
CRL1 and CRL4A, whereas two cytosolic substrates of CRL2, the Rho GTP exchange factor 
VAV 353, and the hypoxia induced factor HIF1α  354,  were not affected. In addition, IkBα, a 
cytosolic substrate of CRL1-βTRCP, was degraded, confirming that the ligase is inactivated 
only in the nucleus. 
The large tegument proteins of herpesviruses are predominantly localized in the cytoplasm of 
the infected cells 355. However, the preferential effect on nuclear cullins and their substrates 
implies that enzymatically active BPLF1 is found in the nucleus. To address this issue, we 
investigated the subcellular localization of BPLF1 in induced Akata-Bx1 cells. Cell lysates 
were labeled with the HA-Ub-VS and FLAG-NEDD8-VS functional probes and 
immunoprecipitated with anti-HA and anti-FLAG specific antibodies. Western blots were 
probed with antibodies to HA, FLAG, and with a rabbit polyclonal serum specific for the 
catalytic N-terminus of BPLF1 (amino acids 1-325). Two de-novo expressed enzymatic 
activities were identified: the full-length BPLF1 and shorter species representing the N-
terminal catalytic domain cross-linked to the probe. Bioinformatics predictions suggested that 
the short fragment might be generated by cleavage at a caspase-1 cleavage site in position 
Asp222. Indeed, the shorter species was not detected when the productive cycle was induced 
in the presence of caspase inhibitors. Furthermore, treatment with the inhibitors abrogated 
nuclear fluorescence suggesting that accumulation of the catalytic N-terminus of BPLF1 in 
the nucleus is dependent on cleavage of the cytosolic protein by caspase-1. Most importantly, 
in line with the nuclear localization of the BPLF1 substrates involved in the regulation of 
productive infection, treatment with caspase-1 inhibitors abrogated the degradation of Cul1 
and Cul4A and consequent stabilization of CDT1 and Cdc25A, which correlated with a 
significant decreased yield of viral DNA. The same effect was observed in the EBV producer 
B95.8 cells line where treatment with caspase-1 inhibitors resulted in a dose-dependent 
inhibition of the release of infectious virus. 
These findings illustrate two important issues: firstly they provide a clear example of how, 
under physiologic conditions of expression, subcellular localization may determine the 
substrate specific function of a viral enzyme; secondly they highlight the contribution of the 
cell to the regulation of viral function that could play important roles in different phases of 
the infection. Caspase-1 is well known as the converging target of danger signals such as 
physical stress, extracellular ATP, bacterial and viral products, that via a sensing molecule 
and adaptors, promotes the assembly of a multisubunit complex known as the inflammasome 
356. The inflammasome triggers the self-activation of caspase-1, which in turn mediates the 
maturation of pro-inflammatory cytokines like interleukin (IL)-1β and IL-18, and executes a 
program of cell death known as pyroptosis 357. Many viruses are known to inhibit the 
inflammasome or block the activity of caspase-1 to counteract antiviral responses 358. Our 
findings highlight a previously unrecognized role of the cellular response to danger signals 
triggered by EBV reactivation in promoting rather than inhibiting virus replication.  
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6 CONCLUSIONS AND FUTURE PROSPECTIVES 
 
EBV is the first human virus to be associated with malignancies but its contribution to the 
pathogenesis of the different tumors that carry the virus has been lively debated. The 
strongest argument in favor of EBV as a “tumor virus” is provided by the clonality of the 
malignant infected cells, which indicates their origin from EBV positive precursor. This 
scenario is supported by the capacity of EBV to immortalize human B-lymphocytes in 
vitro. However, the EBV carrying immunoblastic lymphomas rising in immunosuppressed 
individuals are often regarded as “immunological accidents” rather than “true 
malignancies” while other EBV associated malignancies, most notably BL and HD 
lymphomas, occur in EBV positive and EBV negative variants suggesting that virus 
infection is not a rate limiting step in pathogenesis. Furthermore, the malignant cells are 
phenotypically different from EBV immortalized cell line cells and do not express several 
of the viral proteins required for growth transformation. The work presented in this thesis 
has contributed to this debate by providing new evidences for the capacity of EBV to 
contribute to different aspects of tumor initiation and progression.  
 
In Paper I we have shown that, in addition to its capacity to induce cell proliferation, the 
virus can also promote replicative immortality through activation of a telomerase-
independent pathway of telomere elongation known as ALT. The inherently imprecise 
recombination mechanisms that characterize ALT may give rise to inappropriate repair and 
chromosomal aberrations. Thus, EBV infection may directly induce several key phenotypic 
properties of malignant transformation, including autonomous growth, genomic instability 
and the escape from replicative senescence through activation of recombination-based 
mechanisms for telomere homeostasis. While the results of Paper I identify telomere 
deprotection as one possible mechanism for ALT activation in freshly infected B-
lymphocytes, several important issues remain unresolved, in particular with regard to the 
molecular events involved in shelterin inactivation. A detailed analysis of the components 
of the DNA damage response and repair machineries that are activated in the early phase of 
the infection may identify specific features of the EBV-induced cellular response and 
suggest new ways for interfering with infection.  
In Paper II we have shown that ROS are specifically induced during the early phase of EBV 
infection in order to establish a cellular environment conducive to B-cell immortalization. 
The particular susceptibility of telomere DNA to ROS induced damage suggests a possible 
triggering mechanism for telomere dysfunction that, together with the activation of different 
DNA repair pathways, could select for mutations that provide growth advantages both in 
vitro and in vivo. It remains to be seen how the infected cells overcome the challenge posed 
by the oxidative environment that appears to be required for efficient expression of growth 
promoting viral and cellular factors such as LMP1 and phosphorylated STAT3. Conceivably, 
the activation of cellular antioxidant pathways could contribute to quench the burst of ROS 
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observed during the initial phases for the infection. Interestingly, established LCLs appear to 
be less dependent on sustained levels of ROS for LMP1 expression and are also relatively 
insensitive to the inhibition of STA3 phosphorylation induced by Stattic, which emphasizes 
the dynamic nature of the infection process and strengthens the notion of a distinct type of 
virus-host cell interaction occurring in early EBV-infected proliferating B-lymphocytes. A 
particularly interesting observation is that the oxidative environment induced by the virus 
affects the expression of viral microRNAs. Very little is known on how these viral products 
contribute to regulate different phases of the infection and a more detailed analysis of their 
effects on viral and cellular gene expression could provide interesting new insights. Most 
importantly, the finding that ROS quenching during the very early phases of EBV infection 
dramatically decreases the efficiency of B-cell immortalization suggests a new strategy for 
interfering with the infection that may be directly applicable to the clinic, particularly in 
immunosuppressed patients where uncontrolled reactivation of the productive virus cycle 
may promote de novo infection of B lymphocytes. 
In Paper II we could confirm the previously reported observation that detectable levels of 
preformed viral RNAs are delivered to the infected cells by the incoming virions. This 
finding highlights an aspect of EBV infection that has received very little attention, namely 
the capacity of virion components to contribute to the remodeling of the cellular environment 
during the very early phases of the infection.  
In Paper III we have performed a detailed analysis of the activity of one of these virion-
associated components, the large tegument protein BPLF1. We have previously shown that 
BPLF1 is expressed as an early viral protein during the productive cycle of EBV and 
contributes to EBV replication by inactivating cullin ligases through its deneddylase activity. 
Surprisingly this activity appears to be selectively exerted in the nucleus of the infected cells. 
BPLF1 is also a potent deubiquitinase and several candidate substrates for this activity have 
been identified.  Conceivably, while acting as a deneddylase in the nucleus, BPLF1, or 
perhaps the unprocessed form of the enzyme, may act as an ubiquitin-specific deconjugase in 
the cytoplasm of the infected cells. It remains to be seen whether different sets of cellular and 
viral substrates may be affected during these phases of the infection. The identification of 
additional BPLF1 substrates, possibly based on co-immunoprecipitation and mass 
spectrometry analysis, will be required to answer these questions. We have found that 
localization of the deneddylase activity to the nucleus is dependent on cleavage of the 
catalytic N-terminus by caspase-1. Cleavage may also activate the enzymatic activity as 
suggested in Paper III by the more efficient labeling of the caspase-1 cleavage product 
compared to the full-length protein. The importance of this event in the context of the 
productive cycle is confirmed by the observation that treatment with caspase inhibitors 
inhibited virus replication and prevented the release of infectious virus. It will be interesting 
to test whether cleavage of the virion-associated BPLF1 is also required for its activity. If so, 
treatment with caspase-1 inhibitors may provide an additional tool for interfering with the 
initial events of EBV infection.  
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